Aleksandra Filipovic MD PhD, is the Head of Oncology at PureTech Health, a clinical stage biopharma dedicated to developing novel therapies for challenging indications in oncology and other disease areas. There, Dr Filipovic leads development on novel compounds for solid tumors and hematological malignancies, from target identification, biomarker and companion diagnostic development to Phase 1 and late Phase 2 clinical trials. She is a medical oncologist practicing at Imperial College London where she also holds an honorary lecturer position. She acquired her PhD and completed post-doctoral studies at Imperial College, in the area of cancer cell biology and from there worked at Bristol Myers Squibb and consulted for AstraZeneca, before joining PureTech. In addition to her clinical and scientific/drug development roles, Dr Filipovic is a Scientific and Clinical Advisor to Sharing Progress in Cancer Care (SPCC), a global educational platform dedicated to the all facets of the oncology community worldwide, where she designs and facilitates educational and innovation content. Aleksandra also sits on the editorial Board of the Holistic Integrative Oncology Journal and in her purpose of integrating medical care and holistic healing, Aleksandra is an accredited holistic clinician and founder of the The H.E.A.L. Clinic, a place where whole body intelligence comes alive. She integrates a whole patient centered approach into all areas of her practice. LinkedIn:
Aleksandra Filipovic MD Ph.D. | LinkedIn